TY - JOUR
T1 - Measurement of the energy-generating capacity of human muscle mitochondria
T2 - Diagnostic procedure and application to human pathology
AU - Janssen, Antoon J.M.
AU - Trijbels, Frans J.M.
AU - Sengers, Rob C.A.
AU - Wintjes, Liesbeth T.M.
AU - Ruitenbeek, Wim
AU - Smeitink, Jan A.M.
AU - Morava, Eva
AU - Van Engelen, Baziel G.M.
AU - Van Den Heuvel, Lambert P.
AU - Rodenburg, Richard J.T.
PY - 2006/5
Y1 - 2006/5
N2 - Background: Diagnosis of mitochondrial disorders usually requires a muscle biopsy to examine mitochondrial function. We describe our diagnostic procedure and results for 29 patients with mitochondrial disorders. Methods: Muscle biopsies were from 43 healthy individuals and 29 patients with defects in one of the oxidative phosphorylation (OXPHOS) complexes, the pyruvate dehydrogenase complex (PDHc), or the adenine nucleotide translocator (ANT). Homogenized muscle samples were used to determine the oxidation rates of radiolabeled pyruvate, malate, and succinate in the absence or presence of various acetyl Co-A donors and acceptors, as well as specific inhibitors of tricarboxylic acid cycle or OXPHOS enzymes. We determined the rate of ATP production from oxidation of pyruvate. Results: Each defect in the energy-generating system produced a specific combination of substrate oxidation impairments. PDHc deficiencies decreased substrate oxidation reactions containing pyruvate. Defects in complexes I, III, and IV decreased oxidation of pyruvate plus malate, with normal to mildly diminished oxidation of pyruvate plus camitine. In complex V defects, pyruvate oxidation improved by addition of carbonyl cyanide 3-chlorophenyl hydrazone, whereas other oxidation rates were decreased. In most patients, ATP production was decreased. Conclusion: The proposed method can be successfully applied to the diagnosis of defects in PDHc, OXPHOS complexes, and ANT.
AB - Background: Diagnosis of mitochondrial disorders usually requires a muscle biopsy to examine mitochondrial function. We describe our diagnostic procedure and results for 29 patients with mitochondrial disorders. Methods: Muscle biopsies were from 43 healthy individuals and 29 patients with defects in one of the oxidative phosphorylation (OXPHOS) complexes, the pyruvate dehydrogenase complex (PDHc), or the adenine nucleotide translocator (ANT). Homogenized muscle samples were used to determine the oxidation rates of radiolabeled pyruvate, malate, and succinate in the absence or presence of various acetyl Co-A donors and acceptors, as well as specific inhibitors of tricarboxylic acid cycle or OXPHOS enzymes. We determined the rate of ATP production from oxidation of pyruvate. Results: Each defect in the energy-generating system produced a specific combination of substrate oxidation impairments. PDHc deficiencies decreased substrate oxidation reactions containing pyruvate. Defects in complexes I, III, and IV decreased oxidation of pyruvate plus malate, with normal to mildly diminished oxidation of pyruvate plus camitine. In complex V defects, pyruvate oxidation improved by addition of carbonyl cyanide 3-chlorophenyl hydrazone, whereas other oxidation rates were decreased. In most patients, ATP production was decreased. Conclusion: The proposed method can be successfully applied to the diagnosis of defects in PDHc, OXPHOS complexes, and ANT.
UR - http://www.scopus.com/inward/record.url?scp=33646347898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646347898&partnerID=8YFLogxK
U2 - 10.1373/clinchem.2005.062414
DO - 10.1373/clinchem.2005.062414
M3 - Article
C2 - 16543390
AN - SCOPUS:33646347898
SN - 0009-9147
VL - 52
SP - 860
EP - 871
JO - Clinical Chemistry
JF - Clinical Chemistry
IS - 5
ER -